Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly.
Looking at options history for Eli Lilly LLY we detected 23 trades.
If we consider the specifics of each trade, it is accurate to state that 39% of the investors opened trades with bullish expectations and 26% with bearish.
From the overall spotted trades, 8 are puts, for a total amount of $554,085 and 15, calls, for a total amount of $4,583,508.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $500.0 to $1260.0 for Eli Lilly during the past quarter.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $500.0 to $1260.0 in the last 30 days.
Eli Lilly 30-Day Option Volume & Interest Snapshot
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | CALL | SWEEP | NEUTRAL | 01/17/25 | $410.8 | $406.5 | $410.8 | $500.00 | $2.0M | 488 | 50 |
| LLY | CALL | SWEEP | BEARISH | 01/17/25 | $410.8 | $406.6 | $409.0 | $500.00 | $2.0M | 488 | 50 |
| LLY | PUT | SWEEP | BEARISH | 10/25/24 | $11.0 | $9.2 | $11.0 | $910.00 | $168.3K | 1.3K | 176 |
| LLY | PUT | TRADE | BULLISH | 11/01/24 | $17.7 | $16.5 | $16.5 | $875.00 | $165.0K | 98 | 0 |
| LLY | CALL | TRADE | BEARISH | 03/21/25 | $149.75 | $148.0 | $148.67 | $800.00 | $74.3K | 174 | 10 |
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Where Is Eli Lilly Standing Right Now?
- With a volume of 207,482, the price of LLY is down -0.58% at $903.84.
- RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
- Next earnings are expected to be released in 7 days.
What Analysts Are Saying About Eli Lilly
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $1052.6666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Bernstein has revised its rating downward to Outperform, adjusting the price target to $1100. * Reflecting concerns, an analyst from Deutsche Bank lowers its rating to Buy with a new price target of $1025. * An analyst from Truist Securities persists with their Buy rating on Eli Lilly, maintaining a target price of $1033.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
